The Myocardial Protective Effects Of Recombinant Human On The Patients Undergoing Cardiac Valve Replacement

Objective To investigate the myocardial protective effects and its mechanism of recomrecombinant human erythropoietin (rHuEPO) in patients with cardiac valve replacement under cardio-pulmonary bypass(CPB).Methods Thirty patients with rheumatic heart disease undergoing mitral valve replacement randomly were random divided into two groups(experimental group and control group, 15 patients in each group). The experimental group were administrated rHuEPO 200IU/kg (once daily, hypodermic injection) lasting 3 days before surgery. Other experimental conditions were no difference between two groups.â‘ Before operation and the third day after surgery, we calculated the RBC,Hb,Hct and PLt of the peripheral blood.â‘¡We determined the level of creatine kinase (CK), MB isoenzyme of creatine kinase (CK-MB), lactate dehydrogenase (LDH) and troponin I(cTnI) of the peripheral blood at the different time(before operation, after aorta opened at 2nd hour, 6th hour, 12th hour, 24th hour)..Resultsâ‘ The level of RBC,Hb,Hct and Plt were no significant difference between two groups pre- and post-operation(P>0.05).(2)The level of CK and cTnI were no significant difference between two groups pre-opration(P>0.05), and the level of CK and cTnI of the experimental group were significantly lower than that of the control group after aorta opened(P<0.05).Conclusion The outcomes suggested that rHuEPO had the benefit on protecting myocardium of patients who undergoing valve replacement underextracorporeal circulation, and rHuEPO would not effect the level of RBC, Hb, Hct, and Plt. There was no potential hazard of thrombosis for the patients who administrated with rHuEPO before opration..